Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 15.29
(3.59%)
CNY 15.29
(3.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 136.93 Million CNY | 41.73% |
| 2022 | 96.62 Million CNY | -3.67% |
| 2021 | 100.3 Million CNY | -25.24% |
| 2020 | 134.17 Million CNY | -5.21% |
| 2019 | 141.55 Million CNY | 21.42% |
| 2018 | 116.57 Million CNY | 241.26% |
| 2017 | 34.16 Million CNY | -8.6% |
| 2016 | 37.37 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 35.64 Million CNY | 6.87% |
| 2024 Q2 | 32.56 Million CNY | -8.63% |
| 2024 Q3 | 3.55 Million CNY | -94.68% |
| 2023 FY | 136.93 Million CNY | 41.73% |
| 2023 Q1 | 58.74 Million CNY | 269.42% |
| 2023 Q2 | 28.22 Million CNY | -51.95% |
| 2023 Q3 | 16.61 Million CNY | -41.12% |
| 2023 Q4 | 33.35 Million CNY | 100.69% |
| 2022 Q4 | 15.9 Million CNY | 22.5% |
| 2022 Q1 | 40.14 Million CNY | 297.09% |
| 2022 Q3 | 12.98 Million CNY | -52.95% |
| 2022 Q2 | 27.59 Million CNY | -31.28% |
| 2022 FY | 96.62 Million CNY | -3.67% |
| 2021 Q3 | 29.99 Million CNY | 8.6% |
| 2021 Q1 | 29.31 Million CNY | -27.89% |
| 2021 FY | 100.3 Million CNY | -25.24% |
| 2021 Q4 | -20.37 Million CNY | -167.91% |
| 2021 Q2 | 27.62 Million CNY | -5.77% |
| 2020 Q3 | 39.74 Million CNY | 27.89% |
| 2020 Q4 | 40.64 Million CNY | 2.28% |
| 2020 FY | 134.17 Million CNY | -5.21% |
| 2020 Q1 | 22.71 Million CNY | -71.72% |
| 2020 Q2 | 31.07 Million CNY | 36.83% |
| 2019 Q1 | 21.03 Million CNY | 0.0% |
| 2019 FY | 141.55 Million CNY | 21.42% |
| 2019 Q2 | 26.32 Million CNY | 25.18% |
| 2019 Q4 | 80.29 Million CNY | 477.83% |
| 2019 Q3 | 13.89 Million CNY | -47.21% |
| 2018 FY | 116.57 Million CNY | 241.26% |
| 2017 FY | 34.16 Million CNY | -8.6% |
| 2016 FY | 37.37 Million CNY | 0.0% |